To summarize, PSMA PET/CT is at present the best diagnostic tool for intermediate and high-risk prostate cancer patients, demonstrating excellent diagnostic performance for both N and M staging and likely superior to mpMRI in the detection of locoregional lymph node metastasis. This evidence concerns the gene FOLH1 and prostate cancer.